Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Koran, L. M. Articles by Robinson, D. Search for Related Content PubMed Citation Articles by Koran, L. M. Articles by Robinson, D. Obsessive-Compulsive Disorder Antidepressants

Efficacy of Sertraline in the Long-Term Treatment of Obsessive-Compulsive Disorder

OBJECTIVE: Obsessive-compulsive disorder (OCD) typically begins early in life and has a chronic course. Despite the need for long-term treatment, the authors found no placebo-controlled studies that have examined the relapse-prevention efficacy of maintenance therapy. METHOD: Patients who met criteria for response after 16 and 52 weeks of a single-blind trial of sertraline were randomly assigned to a 28-week double-blind trial of 50–200 mg/day of sertraline or placebo. Primary outcomes after the double-blind trial were full relapse, dropout due to relapse or insufficient response, or acute exacerbation of OCD symptoms. RESULTS: Of 649 patients at baseline, 232 completed 52 weeks of the single-blind trial and met response criteria. Among the 223 patients in the double-blind phase of the study, sertraline had significantly greater efficacy than placebo on two of three primary outcomes: dropout due to relapse or insufficient clinical response (9% versus 24%, respectively) and acute exacerbation of symptoms (12% versus 35%). Sertraline resulted in improvement in quality of life during the initial 52-week trial and continued improvement, significantly superior to placebo, during the subsequent 28-week double-blind trial. Long-term treatment with sertraline was well tolerated. Over the entire study period, less than 20% of the patients stopped treatment because of adverse events. CONCLUSIONS: Sertraline demonstrated sustained efficacy among patients responding to treatment and was generally well tolerated during the 80-week study. During the study’s last 28 weeks, sertraline demonstrated greater efficacy than placebo in preventing dropout due to relapse or insufficient clinical response and acute exacerbation of OCD symptoms.

This article has been cited by other articles:

				L. M. Koran M.D. Obsessive-Compulsive Disorder: An Update for the Clinician Focus, January 1, 2007; 5(3): 299 - 313. [Full Text] [PDF]

				M. H. Rapaport, C. Clary, R. Fayyad, and J. Endicott Quality-of-Life Impairment in Depressive and Anxiety Disorders Am J Psychiatry, June 1, 2005; 162(6): 1171 - 1178. [Abstract] [Full Text] [PDF]

				A. Kaplan and E. Hollander A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder Focus, July 1, 2004; 2(3): 454 - 461. [Abstract] [Full Text] [PDF]

				A. Kaplan and E. Hollander A Review of Pharmacologic Treatments for Obsessive-Compulsive Disorder Psychiatr Serv, August 1, 2003; 54(8): 1111 - 1118. [Abstract] [Full Text] [PDF]

				A. K. JAINER and O.A. ONALAJA Consolidated Standard of Reporting Trials Guidelines Am J Psychiatry, January 1, 2003; 160(1): 191 - 192. [Full Text]

				G M. Soomro Sertraline reduced patient dropout rates and acute exacerbation of symptoms in obsessive compulsive disorder Evid. Based Ment. Health, November 1, 2002; 5(4): 115 - 115. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us